Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dna X (SONM) Operating Leases (2021 - 2023)

Dna X filings provide 3 years of Operating Leases readings, the most recent being $55000.0 for Q4 2023.

  • On a quarterly basis, Operating Leases fell 16.67% to $55000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was $55000.0, a 16.67% decrease, with the full-year FY2023 number at $55000.0, down 16.67% from a year prior.
  • Operating Leases hit $55000.0 in Q4 2023 for Dna X, down from $120000.0 in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $1.8 million in Q1 2022 to a low of $55000.0 in Q4 2023.
  • Median Operating Leases over the past 3 years was $183000.0 (2023), compared with a mean of $478000.0.
  • Biggest five-year swings in Operating Leases: changed 0.0% in 2022 and later tumbled 88.37% in 2023.
  • Dna X's Operating Leases stood at $66000.0 in 2021, then changed by 0.0% to $66000.0 in 2022, then decreased by 16.67% to $55000.0 in 2023.
  • The last three reported values for Operating Leases were $55000.0 (Q4 2023), $120000.0 (Q3 2023), and $183000.0 (Q2 2023) per Business Quant data.